600 Shares in Exact Sciences Corporation $EXAS Acquired by Country Trust Bank

Country Trust Bank purchased a new position in shares of Exact Sciences Corporation (NASDAQ:EXAS) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm purchased 600 shares of the medical research company’s stock, valued at approximately $32,000.

Several other institutional investors also recently made changes to their positions in EXAS. Massachusetts Financial Services Co. MA acquired a new stake in shares of Exact Sciences during the 2nd quarter worth $157,805,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in Exact Sciences by 120.1% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 3,128,958 shares of the medical research company’s stock valued at $135,453,000 after acquiring an additional 1,707,287 shares during the period. Nuveen LLC acquired a new stake in Exact Sciences during the first quarter worth about $45,334,000. Price T Rowe Associates Inc. MD raised its holdings in shares of Exact Sciences by 11.2% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 6,403,872 shares of the medical research company’s stock worth $277,225,000 after purchasing an additional 643,631 shares during the period. Finally, Vanguard Group Inc. lifted its stake in shares of Exact Sciences by 3.6% in the 1st quarter. Vanguard Group Inc. now owns 17,637,674 shares of the medical research company’s stock valued at $763,535,000 after purchasing an additional 617,384 shares in the last quarter. 88.82% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Exact Sciences

In other Exact Sciences news, EVP Jacob A. Orville sold 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 19th. The stock was sold at an average price of $75.00, for a total transaction of $375,000.00. Following the completion of the sale, the executive vice president owned 23,237 shares in the company, valued at $1,742,775. This trade represents a 17.71% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director James Edward Doyle sold 2,000 shares of the company’s stock in a transaction that occurred on Thursday, October 9th. The shares were sold at an average price of $60.00, for a total value of $120,000.00. Following the completion of the transaction, the director directly owned 57,962 shares in the company, valued at approximately $3,477,720. The trade was a 3.34% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 9,858 shares of company stock worth $695,289 in the last 90 days. 1.20% of the stock is owned by corporate insiders.

Exact Sciences Price Performance

EXAS opened at $101.45 on Thursday. Exact Sciences Corporation has a twelve month low of $38.81 and a twelve month high of $101.87. The firm has a market cap of $19.22 billion, a price-to-earnings ratio of -18.68, a PEG ratio of 5.56 and a beta of 1.34. The company has a current ratio of 2.89, a quick ratio of 2.56 and a debt-to-equity ratio of 0.94. The company has a fifty day simple moving average of $65.74 and a 200 day simple moving average of $56.47.

Exact Sciences (NASDAQ:EXAS) last posted its quarterly earnings data on Monday, November 3rd. The medical research company reported $0.24 earnings per share for the quarter, beating analysts’ consensus estimates of $0.13 by $0.11. The company had revenue of $850.74 million during the quarter, compared to analysts’ expectations of $810.42 million. Exact Sciences had a negative net margin of 34.19% and a negative return on equity of 1.75%. The firm’s revenue for the quarter was up 20.0% on a year-over-year basis. During the same period in the prior year, the company posted ($0.21) EPS. Exact Sciences has set its FY 2025 guidance at EPS. Equities research analysts expect that Exact Sciences Corporation will post -0.58 EPS for the current fiscal year.

Analyst Ratings Changes

EXAS has been the subject of a number of research analyst reports. TD Cowen downgraded shares of Exact Sciences from a “strong-buy” rating to a “hold” rating in a research report on Monday. Weiss Ratings reissued a “sell (d-)” rating on shares of Exact Sciences in a research report on Wednesday, October 8th. Barclays reissued an “equal weight” rating and issued a $105.00 target price (up previously from $77.00) on shares of Exact Sciences in a research note on Thursday, November 20th. Royal Bank Of Canada decreased their price target on shares of Exact Sciences from $54.00 to $46.00 and set a “sector perform” rating for the company in a research report on Thursday, August 7th. Finally, Canaccord Genuity Group lowered Exact Sciences from a “buy” rating to a “hold” rating and raised their price objective for the company from $85.00 to $105.00 in a research report on Tuesday. Two equities research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, eighteen have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Exact Sciences presently has an average rating of “Hold” and an average target price of $83.61.

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.